The landscape of drug discovery is undergoing a seismic shift. For decades, the gold standard of preclinical toxicology—the process of assessing the safety of a new drug before it ever reaches human trials—has relied on a linear, resource-heavy model: design an animal study, administer the compound, sacrifice the subjects, and have a pathologist manually inspect glass slides. Once the report was filed, those slides were relegated to long-term storage, effectively ending their utility.
Today, that "one-way street" is being transformed into a dynamic, data-rich loop. Driven by the maturation of digital pathology and the push for New Approach Methodologies (NAMs), researchers are discovering that the past is the key to the future. By mining archived tissue and digitizing histopathology, the industry is poised to drastically reduce the number of animals required for safety assessments, ushering in a new era of efficiency and ethics.
The Digital Evolution: From Pandemic Necessity to Data Powerhouse
Digital pathology began as a niche solution to logistical bottlenecks during the COVID-19 pandemic. With laboratories locked down and travel restricted, pathologists required a way to perform sign-outs remotely. The transition to high-resolution digital slide scanning—once a luxury—became an operational survival strategy.
However, as Dr. Aleksandra Zuraw, DVM, PhD, a veterinary pathologist at Charles River Laboratories, observes, the true breakthrough was not just the ability to view slides on a monitor; it was the realization that a slide is fundamentally a collection of pixels.
"Before, the pathology endpoint was just a report," Dr. Zuraw explains. "Now you have the digitized slide, which is pixels." By treating tissue images as high-dimensional data, researchers can apply machine learning algorithms to identify subtle biological patterns—molecular changes that are often invisible to the human eye but predictive of drug efficacy or toxicity.
Chronology of a Shift: From Analog Archives to Virtual Models
The transition toward digital-first preclinical research has been a multi-year effort defined by several critical milestones:
- 2020–2021: The pandemic-induced surge in digital adoption creates a massive repository of digitized histological data, providing the foundational datasets for AI training.
- 2022: The enactment of the FDA Modernization Act 2.0 signals a regulatory sea change, legally allowing non-animal methods to serve as the basis for human clinical trial applications.
- April 2024: Charles River Laboratories launches its "Alternative Methods Advancement Project," signaling a strategic pivot toward reducing animal reliance through data-driven innovation.
- April 2025: The FDA releases a formal roadmap for reducing animal testing in preclinical safety, prioritizing the transition for monoclonal antibodies and signaling a long-term goal of making NAMs the industry default.
- September 2026: Further FDA regulatory updates provide concrete, actionable guidance on how companies can validate and implement these digital alternatives.
Virtual Control Groups: The Arithmetic of Replacement
One of the most immediate impacts of this digital transition is the development of "virtual control groups." In traditional toxicology studies, a significant portion of animals are used solely as control subjects to establish a baseline for comparison.
"Control animals are always a big fraction of every study," notes Dr. Zuraw. By leveraging vast, historical databases of digitized pathology from previous, well-documented studies, researchers can now create "matched" virtual control groups.
The strategy is simple in theory but complex in execution: by comparing a new treatment group against a robust set of historical data that accounts for study conditions, age, and breed, the need for concurrent control animals is substantially reduced. The primary hurdle is establishing rigorous comparability. Charles River and other industry leaders are currently building the data infrastructure required to ensure these virtual controls are statistically sound and regulators are satisfied.
Archived Tissue as a "Time Capsule" of Molecular Insight
When toxicology studies conclude, the physical legacy is often a collection of formalin-fixed, paraffin-embedded (FFPE) blocks. Historically, these were "dead" assets. Now, they are being viewed as dormant data reservoirs.
Molecular tests performed on these stored samples allow researchers to answer questions that arise long after the original study has ended. If a novel hypothesis emerges regarding a drug’s mechanism of action, researchers can return to the archived FFPE blocks, perform molecular profiling, and correlate the findings with the original pathology report. This eliminates the need for "repeat" animal studies, which were previously the only way to investigate post-study inquiries.
The 2025 OECD guidance on omics analysis has further codified this practice, providing a framework for how preserved tissue can be used to support sophisticated investigations into gene expression and protein activity. As Dr. Zuraw puts it, "You don’t lose the context of the study. You can extract more from the same animals, from the same blocks, without running a new experiment."
Implications: The Snowball Effect of Digital Adoption
The move toward digital pathology is not happening in isolation; it is part of a broader, interdisciplinary effort to replace traditional animal models.
Virtual Staining: The Next Frontier
Beyond simply digitizing existing slides, researchers are experimenting with "virtual staining." By capturing unstained tissue sections with advanced scanners, software can generate the appearance of a stain, such as the standard hematoxylin and eosin (H&E) stain, via deep learning. This eliminates the chemical processing steps, reduces the environmental impact of lab reagents, and speeds up the entire histology workflow.
Regulatory Transformation
The FDA’s roadmap is clear: within three to five years, the agency aims to flip the paradigm. Currently, animal studies are the standard, and non-animal methods are the "alternative." The goal is to make NAMs the default, with animal studies reserved for cases where no other path provides sufficient data.
The Role of Early Adopters
For this to become a global reality, the burden of proof rests on early adopters. By demonstrating that digital models and virtual controls produce results as reliable as—or more reliable than—traditional methods, these pioneers provide the "precedent" needed for industry-wide adoption.
"You still need enough early adopters to generate precedent," Dr. Zuraw emphasizes. "Those early adopters will embrace the guidance, figure it out, and troubleshoot, and then others can build on their work without reinventing the wheel."
Conclusion: A More Ethical and Efficient Future
The integration of digital pathology into the drug discovery pipeline represents one of the most promising developments in modern science. By treating every slide as a permanent, searchable, and re-analyzable piece of data, the industry is effectively "recycling" its research assets.
This shift is not merely a matter of convenience; it is a profound ethical advancement. As the "snowball effect" of digital adoption gains momentum, the reliance on animal subjects will continue to wane, replaced by sophisticated computational models that offer a deeper, more granular understanding of human biology. Through the lens of a digital scanner, the future of medicine is becoming not only more precise but significantly more humane.
About the Author
